drugset / Trial / NCT01191359

Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch

NCT01191359 ↗

Phase 2 Completed 66 enrolled ALK-Abelló A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

Multicentre Phase II trial, comparing two different administration routes of SLITonePLUS Birch in regard to pharmacodynamic efficacy and tolerability.

Timeline

Start
2010-01
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator SLITone birch Unknown 200 unknown Subcutaneous

Indications